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ABSTRACT
Background. Muscle cramps and pain associated with 
them can be seen in patients with amyotrophic lateral scle-
rosis (ALS) and are known to reduce the quality of life. 
Pharmacological treatment may not benefit all patients in 
treating these cramps. We assess the efficacy of Onabotuli-
num toxin A (BTX-A) in the treatment of lower limb cramps 
in patients with ALS.
Methods. This retrospective chart review included a to-
tal of ten patients with ALS who suffered from pain due to 
lower limb cramps and were managed with BTX-A. Data 
including patient demographics, visual analog pain scale at 
different intervals during follow up, ALS functional rating 
scale and site of onset of ALS symptoms were documented. 
The pain score at baseline (before administration), at 3 
months follow up and at 6 months follow up were compared 
using Wilcoxon test to assess BTX-A’s efficacy.
Results. A significant improvement in average pain score 
due to cramps from baseline to the 6-month interval with 
a change of 3.1±0.7 (p<0.05,95%CI) was seen on the pain 
scale. No adverse events were noted during administration 
or post injections.
Conclusion. Local BTX-A administration is an efficacious 
and safe procedure for improving pain associated with 
cramps in patients with ALS. 
Introduction
Muscle cramps are involuntary contractions of an indi-
vidual muscle or muscle group which can range from mild 
to severe, and is known to reduce a patient’s quality of life by 
negatively affecting sleep and causing pain lasting for days. 
[1,2] Various physiological states are commonly associated 
with cramps, including pregnancy and fatigue. [3-7]. There 
are two main theories describing the origin of a cramp - 
the unusual arousal of terminal branches of motor axons, 
and hyperactive motor neurons in the spine. [3,7-14] These 
two processes can occur simultaneously thereby leading to 
muscle hyperactivity presenting as a cramp.[9]
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disorder characterized by degeneration of anterior 
horn cells. Cramps are one of the most commonly reported 
symptoms with up to 90% of the patients diagnosed with 
ALS having them during the course of the disease.[15,16,17] A 
study reported that about 56% patients with cramp require 
treatment for the same.[18] They have also been reported to 
be the presenting symptom and may precede weakness and 
wasting by several months.[19,20] Cramps in ALS patients 
are caused by excitation of glutamate, triggering the ran-
dom release of motor nerves, which eventually progress to 
muscle fibers.[4]
Currently, treatment for ALS is centered around symp-
tom management.[21-23] Typical treatments for cramps and 
the pain associated with it include antiepileptic drugs, qui-
nine, and magnesium supplements, which are known to 
have unpleasant effects and are not efficacious.[24-27] The 
use of vitamin E, gabapentin, and quinidine have been in-
vestigated for the relief of cramps in ALS patients, but none 
were successful in alleviating cramps.[28-31] Mexiletine, a 
sodium channel blocker has been demonstrated to reduce 
cramp and cramp induced pain without affecting the pro-
gression of the disease.[32] Another effective management 
modality which has proved to be efficacious is the use of 
onabotulinum toxin A (BTX-A) which works by preventing 
acetylcholine release at the neuromuscular junction there-
by relaxing the muscle and ceasing the pain caused due to 
cramps.[33,34,35]
The purpose of our study is to assess the efficacy of 
botulinum toxin in reducing lower limb cramp pain in ALS 
patients. 
Materials and Methods
Our study is a retrospective chart review of patients 
that attended a University based hospital approved by the 
Institutional review board (IRB) and the IRB waived the 
need to collect informed consent for this study. The study 
population included patients with ALS aged more than 18 
years who were undergoing care our hospital for the same. 
These patients had undergone BTX-A administration 
for managing pain due to cramps by the same physician. 
Only patients with lower limb cramps and at least 6 months 
follow up during the study period were included. All pa-
tients in this study had tried and failed two or more medi-
cations for cramps (either reached maximum dose with no 
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benefit or had side effects resulting in discontinuation or 
dose limitation). The standardized injection sites for BTX-
A included bilateral gastrocnemius (50 units each), quad-
riceps (50 units each) and intrinsic muscles of the foot (50 
units each). They received injections every three months to 
coincide with their regular clinic visit. A total of 10 patients 
fulfilled the criteria and were made a part of the study.
Information including age, gender, race, site of onset 
of ALS, ALS functional rating scale score and visual ana-
log pain score was collected for these 10 patients. The vi-
sual analog pain score was recorded at baseline before the 
administration of botulinum toxin and was followed up at 
3-month and 6-month intervals from the first injection. 
Results
Out of the 10 patients seven were males. Table 1 sum-
marizes the patient demographics of our study. Our study 
showed the average ALS functional rating scale score 
amongst these patients to be 36.5±5.01. The average pain 
score due to cramps at baseline (before the administration 
of BTX-A), at 3 months follow up and at 6 months follow 
up were 8.8±0.7 (8-10), 6.8±1.5 (4-9) and 5.7±1.4 (4-8) re-
spectively. 
The change in average pain score from baseline to 3 
months follow up was 2±0.8 (p=0.05,95%CI) with corre-
lation coefficient of 0.782. However, a significant improve-
ment in the score from baseline to the 6-month interval 
with a change of 3.1±0.7 (p<0.05,95%CI) was noted. Figure 
1 demonstrates the change in pain scores from before ad-
ministration to 3 month and 6-month intervals. No adverse 
either during the procedure or during interval between in-
jections were reported.
Statistics
The analysis of the data included summarizing patient 
demographics and pain scores in form of descriptive sta-
tistical variables including mean, standard deviation and 
ranges. Comparison of the pain scale at different intervals 
was done using Wilcoxon signed rank test and a correlation 
between them was done. All statistical analyses were done 
using SPSS v22 software (IBM, Armonk, NY). 
Discussion
ALS is characterized by progressive weakness in ab-
sence of pain and sensory loss. Although not a cardinal 
symptom in ALS, pain is bound to occur to patients at some 
point during their illness. Cramps are a leading cause of 
pain in patients with ALS and have been reported to affect 
92% of ALS patients in the USA. Occurring on an average 
of 5.3 cramps per day, they do not correlate with the disease 
severity or duration.[16] They have been reported to occur 
most commonly in the calf and thigh followed by hand and 
foot. Cramps were reported to trend down from the first 
year of the disease to the second and third year although its 
prevalence appears to be stable from the first to the third 
years of ALS and increase during months of illness prior to 
diagnosis.[16] This was one of the rationales why we chose 
the specific sites for injecting BTX-A in these patients.
 Our study assessed the efficacy of BTX-A which has 
been reported to effectively manage cramps in other condi-
tions including benign fasciculation syndrome and diabetic 
neuropathy. [33,36,37] The property of relaxing the muscle 
by preventing acetylcholine release at the neuromuscular 
junction has been utilized in ALS patients to manage spas-
ticity, sialorrhea and dysphagia. [38,39,40] Table 2 summarizes 
the different studies that used medications to manage pain 
as a result of cramps in patients with ALS.
A relatively recent trial by De Carvalho in 2010 aimed 
to assess the efficacy of Memantine when compared to pla-
cebo in 63 participants of the study reported the failure of 
Memantine as a cramp relieving agent.[47] 
A study in 2016 involving 60 patients from 10 cen-
ters randomized 1:1:1 to placebo, mexiletine 300mg/d or 
mexiletine 900mg/d and followed for 12 weeks. Mexiletine 
300 mg/d was found to be safe and well tolerated whereas 
Mexiletine 900mg/d was associated to more discontinua-
tions. Large dose dependent reductions in muscle cramps 
frequency and intensity were reported in patients who 
were on Mexiletine. A dose dependent reduction in pain 
intensity was also noted when compared to placebo (300 
Table 1: Patient demographics
Characteristics of the patients Detail
Age (years) 64.1± 5.48
2.Gender (M/F) 7/3
Ethnicity
•	 Caucasians 9
•	 African American 1
Site of onset of ALS
•	 Lower limb 8
•	 Upper limb 2
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Authors Reference Year of study Medication used Outcome
Norris et al 41 1979 Baclofen Diminution of cramps in 
placebo arm and Baclofen 
arm
Blin et al 42 1989 L-threonine No improvement in cramps
Blin et al 43 1992 L-threonine No improvement in cramps
Gil et al 44 1992 L-threonine alone, 
L-threonine + 
L-isoleucine 
and L-valine 
combination
No change in cramps 
Desnuelle et al 45 2001 Riluzole, Riluzole + 
Vit E 
No significant difference in 
cramps between treatment 
and placebo group
Miller et al 30 2001 Gabapentin No difference between 
treatment and placebo group.
Meininger et al 46 Xaliproden No significant change in 
cramp characteristics.
Weber et al 48 2010 THC No significant change in 
cramp characteristics.
De Carvalho et al 47 Memantine No significant difference 
between two groups.
Weiss et al 32 2016 Mexiletine - 
300mg/d and 
900mg/d
Dose dependent reduction in 
pain intensity
Oskarsson et al 49 2018 Mexiletine 13 out of 18 patients had 
significant reduction in 
cramps due to administration 
of drug.
Our study 2019 Onabotulinum toxin 
A
Significant reduction in 
average pain score from 
before administration to 
6-month interval
Table 2: Summary of studies conducted with different medications that were targeted to provide relief to ALS patients with 
cramps.
mg Mexelitine: 37% placebo, p=0.058; 900mg mexiletine: 
16% of placebo, p=0.025%). There was a decrease in ALS 
FRS-R that was observed and was not different from that 
seen in the placebo group.[32] A multi-center, double blind-
ed, placebo control cross over trial of Mexiletine involv-
ing reported the reduction of cramp frequency in 18 of 20 
patients out of which 13 reductions were attributed to the 
treatment (p<0.05). One of the patients discontinued the 
study due to dizziness while the other initiated an open 
label mexiletine therapy.[49] As compared to Mexiletine, 
the adverse effect profile of BTX-A is less severe which is 
reflected in our study. None of our patients complained of 
any adverse effects and all patients continued using this op-
tion. The improvement in average pain score from before 
administration to follow up at 3 months was insignificant 
while that from before administration to at 6 months follow 
up was significant implying that approximately 6 months 
were needed to get significant improvement in pain due to 
cramps. This implied that BTX-A may be a good option to 
manage pain due to cramps in a long-term setting.
Our study however has notable limitations including a 
small sample size and the use of a subjective pain scale to 
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assess the change in pain from last visit. We also lacked ob-
jective cramp measures. Larger studies including random-
ized clinical trials should be conducted to have a definitive 
conclusion about the efficacy and tolerability of using botu-
linum toxin in the management of pain due to cramps in 
patients with ALS.
Corresponding author and contact information: Raghav 
Govindarajan, govindarajanr@health.missouri.edu
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